{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban%2C+10+mg&page=2", "query": { "intervention": "Rivaroxaban, 10 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban%2C+10+mg&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban%2C+10+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T00:02:08.325Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04508023", "title": "A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care (SOC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1284, "start_date": "2020-08-13", "completion_date": "2022-06-01", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508023" }, { "nct_id": "NCT02810704", "title": "Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Embolism", "Venous Thrombosis" ], "interventions": [ { "name": "Enteric Coated Aspirin", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 18883, "start_date": "2016-12", "completion_date": "2025-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02810704" }, { "nct_id": "NCT05180773", "title": "Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peripartum Cardiomyopathy, Postpartum" ], "interventions": [ { "name": "Bromocriptine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Guideline Directed Medical Therapy for Heart Failure (GDMT)", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Second Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dennis M. McNamara, MD, MS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 250, "start_date": "2022-07-27", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180773" }, { "nct_id": "NCT00329628", "title": "Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4541, "start_date": "2006-02", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2014-10-28", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Benton", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329628" }, { "nct_id": "NCT02921022", "title": "Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cancer", "Advanced Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "PEGPH20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2016-10", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921022" }, { "nct_id": "NCT03864406", "title": "Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Cobicistat", "type": "DRUG" }, { "name": "Darunavir/Cobicistat", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2019-06-04", "completion_date": "2022-12-10", "has_results": true, "last_update_posted_date": "2023-12-01", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03864406" }, { "nct_id": "NCT02833948", "title": "Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Aortic Valve Stenosis", "Cardiovascular Diseases", "Heart Valve Diseases", "Ventricular Outflow Obstruction", "Thrombosis" ], "interventions": [ { "name": "Acetylsalicylic acid", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECRI bv", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2016-05", "completion_date": "2019-03-06", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 4, "location_summary": "Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02833948" }, { "nct_id": "NCT00571649", "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Rivaroxaban placebo", "type": "DRUG" }, { "name": "Enoxaparin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 8101, "start_date": "2007-12", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571649" }, { "nct_id": "NCT03718429", "title": "Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease", "Peripheral Arterial Disease", "Atrial Fibrillation" ], "interventions": [ { "name": "Rivaroxaban 2.5 mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2019-01-14", "completion_date": "2020-08-30", "has_results": true, "last_update_posted_date": "2022-06-27", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 2, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03718429" }, { "nct_id": "NCT02333929", "title": "Validation of Rivaroxaban Assay for US Registration", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Patients Receiving Rivaroxaban Treatment" ], "interventions": [ { "name": "STA- Rivaroxaban Calibrator&Control", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Diagnostica Stago", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2015-03", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-02-14", "last_synced_at": "2026-10-09T00:02:08.325Z", "location_count": 1, "location_summary": "Allentown, Pennsylvania", "locations": [ { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02333929" } ] }